In a 71-year-old man with a blood pressure of 138/101 mm Hg who is experiencing dizziness and is currently taking amlodipine 10 mg daily, metoprolol 25 mg twice daily, and valsartan/hydrochlorothiazide (Diovan‑HCT) 160/25 mg daily, what medication should be prescribed next?

Reduce or Discontinue Metoprolol and Optimize Diuretic Therapy

This patient is experiencing dizziness on a complex four-drug regimen that includes a beta-blocker without clear indication, and the next step should be to substitute the current hydrochlorothiazide with chlorthalidone (12.5-25 mg daily) while reducing or discontinuing metoprolol, as the patient already has adequate BP control (138/101 mmHg) but symptomatic side effects. 1

Current Regimen Analysis

This 71-year-old man is on:

• Amlodipine 10 mg (calcium channel blocker - maximized)
• Metoprolol 25 mg BID (beta-blocker)
• Valsartan/HCTZ 160/25 mg (ARB + thiazide diuretic)

His BP of 138/101 mmHg shows:

• Systolic BP near goal (<140 mmHg)
• Diastolic BP slightly elevated (>90 mmHg)
• Dizziness is a red flag for overtreatment or orthostatic hypotension

Why This Regimen Needs Modification

The Beta-Blocker Problem

The patient is taking metoprolol without any compelling indication mentioned (no history of coronary artery disease, heart failure, or arrhythmia requiring rate control). Current guidelines recommend beta-blockers only when there are specific indications such as angina, post-MI, heart failure with reduced ejection fraction, or heart rate control 2. Beta-blockers can cause:

• Bradycardia contributing to dizziness
• Orthostatic hypotension, especially in elderly patients
• Fatigue and reduced exercise tolerance

The Diuretic Optimization Issue

The patient is on hydrochlorothiazide 25 mg, but guidelines specifically recommend thiazide-like diuretics (chlorthalidone or indapamide) over hydrochlorothiazide for resistant or difficult-to-control hypertension 1. Chlorthalidone is more potent and longer-acting, maintaining efficacy down to eGFR of 30 mL/min/1.73m².

Specific Management Algorithm

Step 1: Address the Dizziness (Immediate Priority)

Check orthostatic vital signs:

• Measure BP and heart rate supine and after 1-3 minutes standing
• If systolic BP drops >20 mmHg or diastolic >10 mmHg, this confirms orthostatic hypotension
• Check heart rate - if <60 bpm, beta-blocker is likely contributing

Reduce or stop metoprolol:

• If no compelling cardiac indication exists, discontinue metoprolol entirely
• If there's concern about abrupt cessation, taper over 1-2 weeks (reduce to 12.5 mg BID, then 12.5 mg daily, then stop)

Step 2: Optimize the Three-Drug Regimen

Following the resistant hypertension algorithm 1, the optimal three-drug combination should be:

1. RAS blocker (valsartan 160 mg) - already at appropriate dose
2. Calcium channel blocker (amlodipine 10 mg) - already maximized
3. Thiazide-like diuretic - needs optimization

Switch from Diovan-HCT to:

• Valsartan 160 mg + chlorthalidone 12.5-25 mg (separate pills initially)
• OR continue valsartan/HCTZ but recognize chlorthalidone would be superior

Step 3: If BP Remains Uncontrolled After Optimization

Only if diastolic BP remains >90 mmHg after addressing dizziness and optimizing the diuretic:

Add spironolactone 25 mg daily as the fourth-line agent 1, 2. This is the evidence-based next step for resistant hypertension, with caution for:

• Monitoring potassium (risk of hyperkalemia with ARB + spironolactone)
• Checking renal function (avoid if eGFR <30 mL/min/1.73m²)
• Monitoring for gynecomastia in men

Critical Caveats

Don't Add Another Drug Yet

The patient's systolic BP is 138 mmHg (near goal) and he's symptomatic. Adding medication would be inappropriate - this is a case for subtraction and optimization, not addition.

Exclude Pseudoresistance

Before considering true resistant hypertension:

• Confirm medication adherence
• Perform 24-hour ambulatory BP monitoring or home BP monitoring to exclude white-coat effect 1
• Ensure proper BP measurement technique
• Review for secondary causes if BP remains uncontrolled

Age-Specific Considerations

At 71 years old, this patient is at higher risk for:

• Orthostatic hypotension (which may explain dizziness)
• Medication-related adverse effects
• Falls related to dizziness

The 2024 ESC guidelines note that patients ≥85 years may benefit from less aggressive initial therapy, though at 71 this patient doesn't fall into that category 2.

Monitoring Plan

After medication adjustment:

• Recheck BP and orthostatic vitals in 2-4 weeks
• Assess resolution of dizziness
• If dizziness persists despite medication adjustment, evaluate for other causes (vestibular, cardiac arrhythmia, anemia)
• Monitor electrolytes and renal function, especially if adding spironolactone

The key principle: This patient needs medication rationalization and optimization, not escalation. The dizziness is a clinical warning sign that should prompt de-escalation of the beta-blocker while optimizing the core three-drug regimen with a more effective diuretic.